These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29119445)

  • 41. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bacteriophages as antibacterial agents].
    Shasha SM; Sharon N; Inbar M
    Harefuah; 2004 Feb; 143(2):121-5, 166. PubMed ID: 15143702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages.
    Dufour N; Debarbieux L; Fromentin M; Ricard JD
    Crit Care Med; 2015 Jun; 43(6):e190-8. PubMed ID: 25803649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Veterinary drug legal situation for oral medication in animal facilities in Germany].
    Buettner-Peter U
    Dtsch Tierarztl Wochenschr; 2008 Aug; 115(8):308-11. PubMed ID: 18717059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms].
    Kochetkova VA; Mamontov AS; Moskovtseva RL; Erastova EI; Trofimov EI; Popov MI; Dzhubalieva SK
    Sov Med; 1989; (6):23-6. PubMed ID: 2799488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Medical innovations in the area of conflict between certification and allowance].
    Möller B; Stockheim M; Kraus T; Weber A
    Dtsch Med Wochenschr; 2010 Oct; 135(42):2088-92. PubMed ID: 20941684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comments on the Guidelines for the Prudent Use of Antibacterial Veterinary Pharmaceuticals (Guidelines for Antibiotics)].
    Hansen W; Kietzmann M
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 2012; 40(3):182-5. PubMed ID: 22688742
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ONC Health IT Certification Program: Enhanced Oversight and Accountability. Final rule.
    Office of the National Coordinator for Health Information Technology, Department of Health and Human Services
    Fed Regist; 2016 Oct; 81(202):72404-71. PubMed ID: 27901561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
    Schneider CK; Schäffner-Dallmann G
    Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Regulatory aspects of the development, licensing, and availability of immunological veterinary medicinal products].
    JungbMck C; Werner E; Von Messling V
    Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):473-7. PubMed ID: 26697714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
    Box RJ; Spielmann H
    Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy.
    Malik DJ; Sokolov IJ; Vinner GK; Mancuso F; Cinquerrui S; Vladisavljevic GT; Clokie MRJ; Garton NJ; Stapley AGF; Kirpichnikova A
    Adv Colloid Interface Sci; 2017 Nov; 249():100-133. PubMed ID: 28688779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bacteriophage applications: where are we now?
    Monk AB; Rees CD; Barrow P; Hagens S; Harper DR
    Lett Appl Microbiol; 2010 Oct; 51(4):363-9. PubMed ID: 20796209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of genotoxicity of herbal medicinal products: a co-ordinated approach.
    Kelber O; Steinhoff B; Kraft K;
    Phytomedicine; 2012 Mar; 19(5):472-6. PubMed ID: 22301069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
    Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
    Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The principle of homologous groups in regulatory affairs of allergen products--a proposal.
    Lorenz AR; Lüttkopf D; May S; Scheurer S; Vieths S
    Int Arch Allergy Immunol; 2009; 148(1):1-17. PubMed ID: 18698143
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bacteriophages: an appraisal of their role in the treatment of bacterial infections.
    Hanlon GW
    Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.